ReviewMediators of inflammation2016
Multiple Sclerosis and Obesity: Possible Roles of Adipokines.
Review in Mediators of inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 104 citations in OpenAlex.
- Obesity and Risk of Pediatric-Onset Multiple Sclerosis (POMS): a Systematic Review and Meta-Analysis.Maedica · 2026Review
- Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Do apelin and ghrelin play a role in multiple sclerosis? The analysis of patients treated with immunomodulatory therapies.Frontiers in immunology · 2026Article
- Unraveling multiple sclerosis: a hidden interaction between intestinal microbiota and host lipid metabolism.Gut microbes · 2025Review
- Evaluation of Selected Serum Adipocytokines in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Immunomodulatory Second-Line Drugs.International journal of molecular sciences · 2025Article
- Unmasking the Silent Threat: Prevalence of Cardiovascular Risk Factors in MS Patients in Bucharest, Romania.Journal of clinical medicine · 2025Article
- (Poly)phenols and Multiple Sclerosis: Results from an Observational Cross-Sectional Study.Antioxidants (Basel, Switzerland) · 2025Article
- The Effect of Bio-Electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients with Multiple Sclerosis: A Triple-Blind Randomized Clinical Trial.Journal of clinical medicine · 2024Article
- Review
- Review
- Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.Journal of neurology · 2024Article
- Usefulness of bioelectrical impedance analysis in multiple sclerosis patients-the interrelationship to the body mass index.Frontiers in neurology · 2024Article
- Review
- The Importance of Managing Modifiable Comorbidities in People with Multiple Sclerosis: A Narrative Review.Journal of personalized medicine · 2023Review
- Article
- Multiple Sclerosis-Related Dietary and Nutritional Issues: An Updated Scoping Review with a Focus on Pediatrics.Children (Basel, Switzerland) · 2023Article
- Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA-A Preliminary Study.International journal of molecular sciences · 2023Article
- Midlife body mass index, central adiposity and neuropsychological performance over 10 years in women living with and without HIV.Frontiers in endocrinology · 2023Article
- Ultra-processed foods consumption is associated with multiple sclerosis severity.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) is an autoimmune disorder of the Central Nervous System that has been associated with several environmental factors, such as diet and obesity. The possible link between MS and obesity has become more interesting in recent years since the discovery of the remarkable properties of adipose tissue. Once MS is initiated, obesity can contribute to increased disease severity by negatively influencing disease progress and treatment response, but, also, obesity in early life is highly relevant as a susceptibility factor and causally related risk for late MS development. The aim of this review was to discuss recent evidence about the link between obesity, as a chronic inflammatory state, and the pathogenesis of MS as a chronic autoimmune and inflammatory disease. First, we describe the main cells involved in MS pathogenesis, both from neural tissue and from the immune system, and including a new participant, the adipocyte, focusing on their roles in MS. Second, we concentrate on the role of several adipokines that are able to participate in the mediation of the immune response in MS and on the possible cross talk between the latter. Finally, we explore recent therapy that involves the transplantation of adipocyte precursor cells for the treatment of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.